Drug Trial Radar · NCT00883558
Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus
Last checked: Nov 20, 2026Latest source record: Sep 8, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
May 2009
Primary completion
Feb 2010
Study completion Apr 2010
Sponsor
- Lead sponsor
- Halozyme TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Apr 17, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Insulin lispro is approved by the Food and Drug Administration (FDA) for the treatment of diabetes mellitus. Recombinant human hyaluronidase (rHuPH20) is approved by the FDA as an aid to the absorption and dispersion of other injectable drugs. In this study, rHuPH20 combined with a non-preserved (NP) formulation of regular human insulin (INSULIN-PH20 NP) will be compared to insulin lispro with respect to absorption and action of insulin.
Conditions
- Diabetes Mellitus, Type 1
Interventions
Insulin LisproDrug
regular human insulinDrug
recombinant human hyaluronidase PH20Drug
Insulin glargineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Postprandial Glucose ExcursionTime frame: Week 14 and Week 26
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Barbara Davis Center for Childhood Diabetes
Aurora, Colorado
Diabetes Research Institute
Miami, Florida
Henry Ford Health System
Detroit, Michigan
Mercury Street Medical
Butte, Montana
UNC Diabetes Care Center/Highgate Specialty Center
Durham, North Carolina
Cleveland Clinic
Cleveland, Ohio
Texas Diabetes and Endocrinology
Austin, Texas
West Olympia Internal Medicine
Olympia, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.